

# Target-Pathogen: a structural bioinformatic approach to prioritize drug targets in pathogens

#### Darío Fernández Do Porto Argentine Consortia of Bioinformatics (BIA) Science School

University of Buenos Aires





## Are pathogens fighting back?

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by a bacteria, parasites, viruses and fungi.

The cost of health care for patients with resistant infections is
higher than care for patients with non-resistant infections due to longer duration of illness, additional tests and use of more expensive drugs.

Globally, 480 000 people develop multi-drug resistant TB each year, and drug resistance is starting to complicate the fight against HIV and malaria, as well.







## New Technologies and new paradigms



### Standard Drug discovery pipeline



### target.sbg.qb.fcen.uba.ar

🔪 🖹 Genomes

🗮 Methodology 🛛 🕐 User Guide

TARGET

PATHOGEN

Tutorial 🚯 About

Target-Pathogen database is a bioinformatic approach to prioritize drug targets in pathogens. Available genomic data for pathogens has created new opportunities for drug discovery and development, including new species, resistant and multiresistant ones. However, this data must be cohesively integrated to be fully exploited and be easy to interrogate. Target-Pathogen has been designed and developed as an online resource to allow genome wide based data consolidation from diverse sources focusing on structural druggability, essentiality and metabolic role of proteins. By allowing the integration and weighting of this information, this bioinformatic tool aims to facilitate the identification and prioritization of candidate drug targets for pathogens. With the structurome and drugome information Target-Pathogen is a unique resource to analyze whole genomes of relevants pathogens.

Select Your Genome

### Whole genome analysis and structurome prediction

#### WG anotation of protein properties

• Localization, Gene Ontology, KEGG, Relevant Residues, PFAM, EC Enzyme, etc...



#### WG protein structure prediction





Structure With Quality Assesment for drug development

## How can we select a protein that binds a Drug like compound?

#### Find pockets?



To identify a POCKET! Fpocket: We implemented a pocket detector program We estimated pocket properties and Determine druggability

#### **Concept of Druggability**





## A pocket inside a protein

- Druggability Score : 0.788
- \* Number of Alpha Spheres :
- \* Total SASA :
- \* Polar SASA :
- \* Apolar SASA :
- \* Volume :
- Mean local hydrophobic density :
- \* Mean alpha sphere radius :
- \* Mean alp. sph. solvent access : 0.479
- Apolar alpha sphere proportion : 0.660
- \* Hydrophobicity score:
- Aminoa Acid Composition
- Distances between Aminocids





#### Relevant Information related to the protein pockets

844.370

322.358

29.833

### Druggability in patogens



### How to select an attractive target from the metabolic point of view









## Discarding side effects





#### **Posible Interferencia**











Genomes / Mycobacterium tuberculosis H37Rv

JOIOWSE THE NEW HELP

Overview Data Priorize Targets Prioritize Pathways



2,195,000	2,200,000	2,205,000	2,210,000	2,215,000
Com in to	o see sequence Zoom in to	o see sequence Zoom -	in to see sequence Zoom in to	o see sequence Zoom in to see seq
Genes mazE5 Rv1945	* Rv1947 Rv1950c vapC14	nigA parE1 vapC35	yrbE3A + mce3A + mce3	← lprM ← Rv1972 Rv19
1939 Rv1941 Rv1944c	LppG Rv1948c Rv1951c Rv1954c	Rv1957 parD1 vapB35	yrbE3B → mce3B →	mce3D → mce3F → Rv1973
mazF5	vapB14 higB	Rv1958c Rv1961 mce3R		ŧ

					- <b>-</b> -																														
	0		500,000	)			1,000,	000		1,	,500,0	000		2	2,000,	000			2,5	00,00	0			3,000,0	00		3,	500,00	0		4	4,000,0	00		
								2.3:22	05221.	.2205	285 (6	6 b)	Go	<u> </u>																					
	2,2	05,225													2,205	,250													2,20	5,275					_
	Sequence	]	P	R		S		E	L		Α	*		Р		А		Р		R	F		Р		G	F	2	S	R		A		S		Т
	S	Г	S	;	I		R		I	S		L	T	·	S		Α		Е		v		S .	R		*	I		Т		R	1		Y	
	F	D	L		D	I	P	N		*	L		D		Q	] ]	R	I	R	G		F		Q		'	D	H	H	A		L		V	P
	TTCG	ACO	с Т С	G	A T	CC	GG	A A	T T	A G	CI	TG	A C	C	A G	C	GC	C	G A	GG	ТТ	T	C   C	A G	GT	A C	G A T	C 7	A C G	C	GC	T A	G	ΤA	CC
	A A G C	TGO	G A G	; C	TA	GO	G C	TT	A A	ТС	G A	AC	TO	G	ТС	G	CG	G (	C T	CC	A A	A	GG	TC	CA	TC	C T A	G	GC	G	CG	A T	С	A T	GG
	E	V	Е		Ι	F	R	I		L	K	(	V		L	j	A	5	S	Т		Е		L	Y		I	1	/	R		*		Y	R
	R	G	R	2	D	·	S		N	A		Q	6	;	A	· · ·	G		L		N	(	3	P		L	D		R		A	1		V	
	N S	]	R	S		G		F	*		S	S		W		R		R		P	K		W		Т	S	5	*	A		S		Т		G
								_								1														1					



Search Gene Product By	
Keyword	
	Q
Gene	
	Q
GO Term Q	

#### H37Rv Pathways Q



#### Statistics

Proteins	4023
? Polypeptide domain	3323
Go	3184
Ec	1067
Polypeptide structural motif	534
? Transmembrane polypeptide region	360
Signal peptide	133

Showing 1 to 7 of 7 entries

## OVERVIEW

Genome Browser. EC and GO searches

#### Protein structure



#### Filter

#### Removes the proteins that do not fullfill ALL the conditions

Notadata Add age P					
Metadata Add New Pr	operties				
Name De	scription			Operation	Value
X druggability Dr Dr dr (hr	uggability score from th uggable: druggability > uggability > 0.7. :tps://www.ncbi.nlm.nil	ne most druggab 0.5 / Highly Drug h.gov/pmc/artic	le pocket. ggable les/PMC401467	> ▼	0.5
X essentiality Cri (ht	tical for the organism s tps://www.ncbi.nlm.nil	urvival h.gov/pubmed/2	26791267	equal	▼ true ▼
X human_offtarget Ma pr	ix identity in a simple b otein	last alignment w	rith a human	< 🔻	0.4

TARGET

Filters

PATHOGEN



	8400	Number of ORFs
	5515	Highly druggable proteins (HD)
	843	HD with a residue inside the druggable pocket reported in the Catalytic Site Atlas database (CSA)
	629	HD, CSA and without homology with any human protein (off-target)
	381	HD, CSA, off-target and essential proteins
	105	HD, CSA, off-target and essential proteins with kinase activity
	65	HD, CSA, off-target and essential proteins with serine/threonine kinase activity
	26	HD, CSA, off-target and essential proteins with serine/threonine kinase activity and involved in intracellular signal transduction
Leishmania major		

### Latent tuberculosis



- M. tuberculosis has the remarkable capacity to survive years within the hostile environment of the macrophage.
- Within the macrophage, tuberculosis bacilli is exposed to RNOS stress.
- There is not treatment for latent tuberculosis.

## How to kill latent M. tuberculosis

- Hipótesis:
  - if we know which proteins are targeted by RNOS and kill M. tuberculosis bacilli, we might be able to inhibit them with drugs, resulting in a synergistic bactericidal effect



What features makes a protein a good target for laten tuberculosis drug selection?

Druggabilty No side effects

Essenciality

**Biologically Relevant** 

Important in the metabolic context



# Scoring function

 $SF = \frac{H+S+R+I}{4} + \frac{Ch+Cy}{2}$ 

#### Score

Sorts all / the filtered proteins by calculating a numeric value o score. Score formula is a weighted linear sum of the protein properties.

	Activity Biologic	al Process	<b>Pathways</b>	Structure	Pocket	Metadata	Add new Proper	rties
	Name	Description				Coefficient	Norm.	
Х	overexpression stress Show distribution	Overexpressed in model (https://www.ncbi.nlm.n		0.25	if is equal to true ▼	0.13		
Х	overexpression starvation Show distribution	Overexpressed in model (https://www.ncbi.nlm.n	of starvation ih.gov/pubmed/	/26791267)		0.25	if is equal to true ▼	0.13
Х	overexpression infection Show distribution	Overexpressed in model (https://www.ncbi.nlm.n	of infection ih.gov/pubmed/	/26791267)		0.25	if is equal to true ▼	0.13

#### Newly and Revalidated Mtb targets

Newly and revalidated *Mtb* targets found using structural druggability, metabolic importance analysis and expression data in infection mimicking conditions. Revalidated targets are taken from [25].

Protein name	Rv	Status	Druggability	Pathway (importance)	Profile expression
Inositol-3-phosphate synthase	Rv0046c	New target	0.719	Myo-inositol biosynthesis (0.3871) L-1-phosphatidyl- inositol biosynthesis (Mycobacteria) (0.6063). mycothiol biosynthesis (0.5370)	Str, Hyp, Sta
3-phosphoshikimate 1-carboxyvinyltransferase	Rv3227	New target	724	Chorismate biosynthesis from 3-dehydroquinate (0.4828)	Str
O-acetylhomoserine aminocarboxypropyltransferase	Rv3340	New target	535	Homocysteine biosynthesis (0.4681)	Hyp, Sta, Inf
3-oxoacyl-[acyl-carrier-protein] synthase 2	Rv2246	New target	709	Mycolate biosynthesis (0.4517) fatty acid biosynthesis initiation II (0.3883) 8-amino-7-oxononanoate biosynthesis I (0.3765)	Str, Hyp
Octanoyltransferase	Rv2217	New target	703	Lipoate biosynthesis and incorporation I (0.4529)	Sta
Bifunctional protein GlmU	Rv1018c	New target	911	UDP-N-acetyl-D-glucosamine biosynthesis I (0.4523)	Str, Hyp, Inf
Rv1465	Rv1465	New target	926	[2Fe–2S] iron-sulfur cluster biosynthesis	Str
1D-myo-inositol 2-acetamido-2-deoxy-alpha-D- glucopyranoside deacetylase	RV1170	Revalidated	781	Mycothiol biosynthesis (0.5370)	Str
Sulfate adenylyltransferase subunit 2	Rv1285	Revalidated	891	Selenate reduction (0.4579) sulfate activation for sulfonation (0.4326)	Str, Hyp, Sta
dTDP-glucose 4,6-dehydratase	Rv3464	Revalidated	676	dTDP-1-rhamnose biosynthesis I (0.4459)	Str
Enoyl-[acyl-carrier-protein] reductase [NADH]	Rv1484	Revalidated	919	8-amino-7-oxononanoate biosynthesis I (0.3765) stearate biosynthesis II (bacteria and plants) (0.3700)	
3-methyl-2-oxobutanoate hydroxymethyltransferase	Rv2225	Revalidated	937	Phosphopantothenate biosynthesis I (0.4351)	Str, Hyp, Inf
Mycocyclosin synthase	Rv2276	Revalidated	887	Mycocyclosin biosynthesis (0.4435)	Нур



## Prioritisize pathways

#### Score

Sorts all / the filtered proteins by calculating a numeric value o score. Score formula is a weighted linear sum of the protein properties.

	¢ Activity	Biological Process	O Localization	Pathways	Structure	Pocket	Netadata					
A	dd new Properti	es						N				
	Name	Description			C	oefficient		Norm.				
Х	centrality	Shortest-path betweenness centrality (normalized) for a 1 0.5 reaction graph.										
X chokepoint The protein catalyzes a chokepoint reaction 1 if is equal to 0. true •												
Sc	Score = centrality + chokepoint											

#### SF=((Emgh+Edeg)/2+Cv+Cy +chk)/4 +Pb



#### Target-Pathogen: a structural bioinformatic approach to prioritize drug targets in pathogens

Ezequiel J. Sosa<sup>1,2</sup>, Germán Burguener<sup>1,2</sup>, Esteban Lanzarotti<sup>1,2</sup>, Lucas Defelipe<sup>1,2</sup>, Leandro Radusky<sup>1,2</sup>, Agustín M. Pardo<sup>3</sup>, Marcelo Marti<sup>1,2,3</sup>, Adrián G. Turjanski<sup>1,2,3,\*</sup> and Darío Fernández Do Porto<sup>1,2,\*</sup>

<sup>1</sup>IQUIBICEN-CONICET, Ciudad Universitaria, Pabellón 2, C1428EHA Ciudad de Buenos Aires, Argentina, <sup>2</sup>Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, C1428EHA Ciudad de Buenos Aires, Argentina and <sup>3</sup>Plataforma de Bioinformática Argentina (BIA), Instituto de Cálculo, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, C1428EHA Ciudad de Buenos Aires, Argentina (BIA), Instituto de Cálculo, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, C1428EHA Ciudad de Buenos Aires, Argentina

Received August 14, 2017; Revised September 29, 2017; Editorial Decision October 12, 2017; Accepted October 16, 2017



### Different Pathogens

- Mycobacterium Tuberculosis (Marti, Piuri, UBA): Database 2014, Tuberculosis 2015
- Corynebacterium paratuberculosis (Acevedo, B. Horizonte): BMC Genomics, 2014; BMC Genomics, 2015, Frontiers in Genomics 2018
- \* Klebsiella pneumoniae (Nicolas, Rio de Janeiro): Scientific Reports 2018
- Leishmania Major (Ramos, UFB, Bahia)
- ✤ Bartonella bacilliformis (Abraham Espinosa, University of São Paulo )
- Trypanozoma Cruzi (Pablo Smircich, Montevideo)
- Staphylococcus aeurus (Dr.Bocco, Universidad de Córdoba)



## Plataforma de Bioinformática Argentina

#### A Turjanski M Martí

**Microorganisms Genomics** Ing. Ezequiel Sosa Dr. Germán Burguener Lic. Agustín Pardo Andrés Fernández Benevento **Federico Serral** 

**Human Genomics** Lic. Jonathan Zayat Dr. Sergio Nemirovsky Dr. Juan Pablo Alracon Sebastian Vishnopolska Lic. Geronimo Dubra



AGENCIA









# Argentina dariofd@gmail.com





